PAA - probably the first bio spec I've seen cash flow positive and SP currently near CR price...seeing how bio sector has been resilient against micro cap sell off decided to build a position for LT hold...
MC of 9m with expected >$3m revenue for FY17...worth a look at current price...
Minimum downside to 4.7c and huge upside...plenty of gaps to fill...
